^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    3d
    Study of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Not yet recruiting, Molecular Partners AG
    New P1/2 trial
    6d
    Rapid-onset Severe Cytokine Release Syndrome With Marked Interleukin-6 Increase and Acute Liver Injury After the First Tarlatamab Dose in SCLC: Case Report. (PubMed, JTO Clin Res Rep)
    Severe CRS and liver injury rapidly developed in the patient after the first tarlatamab dose, which led to treatment discontinuation. This report also presents the temporal changes in serum interleukin-6 levels, highlighting its potential utility as a biomarker for the onset and severity of CRS.
    Journal
    |
    IL6 (Interleukin 6)
    |
    Imdelltra (tarlatamab-dlle)
    6d
    DareonTM: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial primary completion date: Oct 2026 --> Jan 2027
    Trial primary completion date
    |
    obrixtamig (BI 764532)
    11d
    Early Pseudoprogression Mimicking Pneumonitis After Tarlatamab Therapy: A Case Suggestive of Immune Cell-Associated Respiratory Syndrome (ICARS). (PubMed, Respirol Case Rep)
    High-dose methylprednisolone and tocilizumab produced prompt clinical and radiographic improvement; follow-up imaging showed resolution of infiltrates and tumour regression below baseline, consistent with pseudoprogression. We speculate that baseline carcinomatous lymphangitis may predispose to ICARS. Recognising ICARS may prevent misdiagnosis and avoid premature discontinuation of effective therapy.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle) • Actemra IV (tocilizumab)
    20d
    TARLATEM: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Centre Leon Berard
    New P1/2 trial
    |
    temozolomide • Imdelltra (tarlatamab-dlle)
    20d
    A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov)
    P1, N=122, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Gazyva (obinutuzumab) • clesitamig (RG6524)
    23d
    MERLIN: Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Fundación GECP
    New P2 trial
    |
    Imdelltra (tarlatamab-dlle)
    24d
    Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients. (PubMed, Cancer Immunol Immunother)
    This cytokine profiling highlights the complex pathophysiology of CRS and the involvement of diverse cytokine networks beyond the IL-6 axis. These findings may guide future biomarker development, disease classification, and therapeutic strategies beyond IL-6 inhibition, advancing personalized CRS management.
    Journal
    |
    IFNG (Interferon, gamma) • HGF (Hepatocyte growth factor) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Imdelltra (tarlatamab-dlle)
    26d
    DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=269, Active, not recruiting, Amgen | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imdelltra (tarlatamab-dlle)
    26d
    DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy. (PubMed, JTO Clin Res Rep)
    Tarlatamab appeared effective when added to osimertinib. Further analysis of the combination of bispecific DLL3 T-cell engager and EGFR tyrosine kinase inhibitor is warranted to confirm these findings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RB1 mutation • DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tagrisso (osimertinib) • Imdelltra (tarlatamab-dlle)
    27d
    Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1 trial • Checkpoint inhibition
    |
    Hetronifly (serplulimab) • alveltamig (ZG006)
    27d
    ZG006-002: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=265, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=105 --> 265
    Enrollment change
    |
    alveltamig (ZG006)